Combined Hyperlipidemias Polygenic Risk Score

You can have a clean-looking lipid panel today and still carry a genetic setup that pushes both your cholesterol and triglycerides upward over a lifetime. That combination, called combined hyperlipidemia, is one of the strongest drivers of early coronary artery disease, and it is largely inherited through hundreds of small DNA variants rather than one dramatic mutation.

This test reads those variants and turns them into a single number that ranks your inherited tendency against the rest of the population. It tells you something a standard cholesterol test cannot: whether your body is genetically wired to develop a mixed lipid problem, even when your current numbers look acceptable.

What the Score Actually Reads

A polygenic risk score (PRS, a weighted sum of many gene variants linked to a trait) for combined hyperlipidemia adds up the small effects of common DNA letters scattered across your genome that nudge LDL cholesterol and triglycerides higher. In one widely cited approach, the score pulls from roughly 6 million variants for LDL and triglycerides; in East Asian populations, scores aggregating 84 to 549 variants have been used.

The score is derived from genotyping your DNA rather than from any hormone, protein, or analyte circulating in your blood, although the DNA itself is usually obtained from a routine blood or saliva sample. It is a one-time read, so the number does not move with diet, exercise, weight, age, or medications. What it captures is your lifetime starting point for lipid biology, which is why it can flag risk before any cholesterol number crosses a line.

Why Combined Hyperlipidemia Is Worth Catching Early

Combined hyperlipidemia, where LDL cholesterol and triglycerides are both elevated, is the dyslipidemia subtype most strongly tied to coronary artery disease. In one large analysis of UK Biobank participants followed for about 11 years, people with this subtype had the highest hazard for incident coronary artery disease across all dyslipidemia categories.

Most cases are not caused by a single broken gene. In Finnish family studies of familial combined hyperlipidemia (FCH), only about 3% of affected individuals carried a classic single-gene mutation, while 35% had very high polygenic scores for LDL or triglycerides. Combined hyperlipidemia behaves like a polygenic trait built from many small inherited pushes, especially on the triglyceride side.

Coronary Artery Disease Risk

This is where the evidence is strongest. Across large cohorts, a high inherited lipid burden translates into a meaningfully higher chance of coronary artery disease, on top of what your current lipid panel suggests.

Source: Ripatti et al., Circulation: Genomic and Precision Medicine 2020; Gilliland et al., Circulation Research 2024.

What this means for you: in the UK Biobank work, the higher heart disease risk from combined hyperlipidemia held up even after the analysis accounted for non-HDL cholesterol, hypertension, type 2 diabetes, body mass index, smoking, and statin use. The genetics seem to add something the standard panel does not fully capture.

Comparison With Inherited High Cholesterol

Familial hypercholesterolemia (FH, a single-gene cause of very high LDL cholesterol) is the better-known inherited lipid disorder. But the polygenic combined form is roughly five times more common in this analysis, though the exact prevalence depends heavily on which diagnostic criteria are used. Its heart risk sits in the same league as monogenic FH. In a UK Biobank analysis, people with a familial combined hyperlipidemia phenotype had a 2.72-fold higher risk of incident coronary artery disease (95% confidence interval 2.31 to 3.21), while those with monogenic FH had a 1.90-fold risk (95% confidence interval 1.30 to 2.78). The confidence intervals overlap substantially, and the original authors describe the two as carrying similar risk rather than one being clearly higher.

Other work in clinical FH-specialty cohorts has found monogenic FH carrying greater cardiovascular risk than polygenic forms, so which condition appears riskier depends on how the populations are defined and ascertained. The practical takeaway is steadier: a condition without a single dramatic gene mutation can carry risk on the order of the textbook genetic disorder. The combination of inherited polygenic susceptibility with metabolic features like central weight gain and insulin resistance compounds risk in ways neither alone would. Treating combined hyperlipidemia as a polygenic disease, not a milder cousin of FH, is the framework that fits the evidence.

Limits of the Current Science

This is an emerging marker, not a settled clinical test. Adding a lipid polygenic score to traditional risk factors improves prediction of coronary artery disease only modestly, with reported area-under-the-curve gains of 0.03 to 0.06 in East Asian cohorts. Even in European populations, where the underlying data are strongest, adding a polygenic score to standard pooled cohort risk equations produces only small improvements in discrimination, and the incremental value beyond a measured lipid panel is modest. Standardized cutpoints for clinical action do not yet exist, and consensus methods for building and reporting these scores are still being worked out.

Performance also depends on ancestry. Most polygenic scores were built using European cohorts, and they consistently underperform in people of African, East Asian, South Asian, and Latin American backgrounds, with predictive utility reported as up to fivefold lower in African Americans and around twentyfold lower in sub-Saharan Africans compared with European Americans. If your ancestry is not well represented in the reference data, the score is less precise, though it still carries information.

What the Result Means Across Your Life

Because this test reads inherited DNA, the result does not change. You take it once. The value lives in how it shapes everything else you do for the next several decades: how aggressive your cholesterol targets should be, how early you start checking apolipoprotein B (ApoB, a count of all cholesterol-carrying particles that can clog arteries), how seriously you take borderline lipid numbers in your 30s and 40s, and when you push for advanced cardiovascular testing rather than waiting for symptoms.

Your downstream lipid testing, on the other hand, should be frequent. A high polygenic score is a reason to track ApoB, lipoprotein(a), and a full lipid panel at least annually, and more often if you are starting or adjusting therapy. The genes are fixed; the levels they nudge are not.

What to Do With an Out-of-Pattern Result

A high score is a signal to widen your workup, not just retest. If your polygenic risk for combined hyperlipidemia is elevated, the next steps typically include a full lipid panel with ApoB, a lipoprotein(a) test to rule out a separate inherited driver, and markers of insulin resistance such as fasting insulin and triglyceride-to-HDL ratio, since metabolic syndrome features amplify polygenic risk for the combined phenotype.

Earlier coronary calcium scoring becomes more useful with a high score, especially in your 30s or 40s when standard risk calculators tend to underestimate younger adults. A referral to a lipidologist or preventive cardiologist is reasonable if your ApoB or triglycerides are elevated alongside a high score, or if you have a family history of early heart attacks. A genetic counselor can help interpret the result and discuss whether siblings, parents, or children may also benefit from testing.

A low score does not mean low cardiovascular risk overall. It only means you did not inherit much of the polygenic push toward combined hyperlipidemia. Smoking, poor sleep, high blood pressure, sedentary habits, and Lp(a) (lipoprotein little a, an inherited lipid particle measured by a separate test) still need their own attention.

When Results Can Be Misleading

Polygenic risk scores have specific failure modes that differ from blood tests:

• Ancestry coverage: scores built primarily on European data lose accuracy in people of non-European ancestry, so the percentile you receive may not mean the same thing across populations.
• Variant panel limits: the assay only reads the specific variants it was designed to detect, so a normal score does not rule out rare or untested genetic causes of dyslipidemia.
• Misreading the percentile: a 90th percentile result is not a 90% chance of disease, and a result labeled "not high risk" is not the same as "low risk." The score is a relative ranking, not a probability of an event.
• Interpretation in isolation: the score reflects only one slice of inherited cardiovascular risk. Family history, lipoprotein(a), and metabolic health all carry independent weight and should be assessed alongside it.

Why Standard Lipid Tests Are Not Enough on Their Own

A standard lipid panel measures what your cholesterol and triglycerides are doing right now, often heavily influenced by recent diet, weight, alcohol, and medications. A polygenic score reads your inherited setup, which does not shift with breakfast or a treadmill session. The two pieces answer different questions: today's number versus your starting hand.

This becomes most useful when your standard labs look fine but you have a family history of early heart disease, when your lipids are borderline and you cannot tell whether to push harder, or when you are young and want to know whether you are starting the race with a head wind. The score does not replace ApoB or a lipid panel. It adds context that does not change with your next meal.